Transaction details
According to a Form 4 filing with the Securities and Exchange Commission, Sera Prognostics (NASDAQ:SERA) General Counsel Benjamin Jackson sold 1,027 shares of Class A common stock on March 11, 2026. The shares were sold at a weighted average price of $2.04, producing total proceeds of $2,095. Reported trade prices in the transaction ranged from $1.90 to $2.30.
Post-sale holdings and rationale
Following the disposition, Jackson directly holds 114,720 shares of Sera Prognostics. The filing states the sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
Market context
Sera Prognostics shares are trading at $1.99, reflecting a decline of roughly 51% over the past 12 months. InvestingPro analysis cited in the filing indicates a Fair Value estimate of $2.56 for the stock. The filing also notes availability of a broader Pro Research Report that includes coverage of Sera Prognostics alongside more than 1,400 other U.S. equities.
Clinical results
Separately, the company reported results from a large clinical trial evaluating its PreTRM test. The study enrolled 5,018 women and found that using the blood test in conjunction with targeted interventions produced significant reductions in preterm birth risks and improved newborn outcomes. Specifically, the trial results showed a 56% reduction in births before 32 weeks and a 32% reduction in births before 35 weeks. Those findings were published in the peer-reviewed journal PREGNANCY.
Analyst coverage
Jefferies has initiated coverage of Sera Prognostics with a Buy rating and set a price target of $5.00. The analyst firm highlighted the potential of the company’s PreTRM product, which is intended to assess the risk of spontaneous preterm birth in asymptomatic pregnancies.
Takeaway
The insider sale disclosed on March 11 was characterized as a tax-driven transaction tied to RSU vesting. It coincides with clinical data publication and fresh analyst optimism for Sera Prognostics’ diagnostic offering.